A real-world study of immune checkpoint inhibitors in advanced triple-negative breast cancer.

• DOI: 10.1200/jco.2023.41.16_suppl.e13090
• Publication Date: 2023-06-04T14:57:50Z
• Authors: Weihong Zhao; Zheng Zhang; Yadi Zhang; Yimeng Chen; Yimin Zhu; Chuanling Liu; Jiakang Shao; Li Zhang; Mei Liu
• Keywords: Triple-negative breast cancer

e13090 Background: Triple-negative breast cancer (TNBC) is the most aggressive type of cancer. The lack specific targets leads in fewer effective treatments and poor prognosis. Immunotherapy has become a new generation treatment approach addition to surgery, radiotherapy, chemotherapy, endocrine therapy targeted therapy. Immune checkpoint inhibitors (ICIs) have been widely used clinical various tumors changed landscape tumor treatment, but data from real-world studies ICIs for TNBC remain limited. Methods: Clinical patients with advanced treated Chinese People’s Liberation Army General Hospital were collected January 2004 December 2022. effect different factors on patient response prognosis was analyzed using Kaplan-Meier survival curves. relationship between clinical, pathological characteristics, hematological indicators, efficiency univariate multifactorial Cox regressions. Objective Response Rate (ORR), Disease Control (DCR), Progression-free Survival (PFS), Overall (OS), adverse events (AEs) assessed. Results: Eighty-one enrolled study. Median follow-up 26.3 months (range, 16.0 - 36.6 months). Confirmed ORR 32.1% DCR 64.2%. median PFS 4.2 OS 11.0 months. Eastern Cooperative Oncology Group (ECOG) performance status score ≥ 1, applying 2 nd later lines, liver metastases, more than two sites lactate dehydrogenase (LDH) 194.3 U/L, alkaline phosphatase (ALP) 104.7 neutrophil-to-lymphocyte ratio at baseline (bNLR) 2.7, NLR before second dose immunotherapy (NLR2) 2.2, platelet lymphocyte (PLR2) 165.6 associated poorer Patients initial infiltrating lymphocytes (TIL) 20%, derived (dNLR) ≤ 1.9, LDH < U/L bNLR 2.5 prior ICI better Conclusions: tolerable effects, we identified series biomarkers OS. Randomized controlled trials are warranted validate our findings.